Oric stock crashed Wednesday after the company indicated its prostate cancer treatment is roughly as effective as a ...

Abstract Highlights Rinzimetostat is a potent and highly selective next-generation allosteric PRC2 inhibitor targeting the EED subunit that has demonstrated potential best-in-class efficacy and safety ...

In recent days, Oric Pharmaceuticals has come under pressure after Ipsen voluntarily withdrew its EZH2 inhibitor Tazverik ...

Deep inside our cells—each one complete with an identical set of genes—a molecular machine known as PRC2 plays a critical role in determining which cells become heart cells, versus brain or muscle or ...

Cancers emerge from many different paths. One path begins early, in embryonic development, when a protein complex called PRC2, which regulates cell differentiation, identity, and plasticity, becomes ...